Who is sponsoring NCT03906474?

NCT03906474 is sponsored by University of Oxford.

What drugs are being tested in NCT03906474?

Interventions in NCT03906474: Blood-stage controlled human P. falciparum malaria infection.

Is NCT03906474 still recruiting?

NCT03906474 is currently completed. Last updated 8 April 2019.

Last reviewed 2019-04-08 · How we verify

NCT03906474

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection

Completed NA Last updated 8 April 2019

What this trial tests

NA trial testing Blood-stage controlled human P. falciparum malaria infection in Malaria in 11 participants. Completed in 14 February 2019.

Timeline

6 November 2018

Primary endpoint
14 February 2019

14 February 2019

Quick facts

Lead sponsor	University of Oxford
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	11
Start date	6 November 2018
Primary completion	14 February 2019
Estimated completion	14 February 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

Blood-stage controlled human P. falciparum malaria infection — full drug profile →

Conditions studied

Malaria — all drugs for Malaria →

Sponsor

University of Oxford

Who can join

Adults 18 to 50, any sex, with Malaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a clinical study to assess the safety of primary, secondary and tertiary blood-stage controlled human Plasmodium falciparum malaria infection of healthy malaria-naïve UK adults, as well as to evaluate any effect of prior exposure to a blood-stage controlled human malaria infection (CHMI) on the parasite multiplication rate. As a secondary objective, the immune response to primary, secondary and tertiary P. falciparum blood-stage infection, as well as gametocytaemia, will also be assessed.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Repeat controlled human malaria infection of healthy UK adults with blood-stage <i>Plasmodium falciparum</i>: Safety and parasite growth dynamics.
Salkeld J, Themistocleous Y, Barrett JR, Mitton CH, et al · · 2022 · cited 13× · PMID 36072606 · DOI 10.3389/fimmu.2022.984323
A systematic analysis of the human immune response to Plasmodium vivax.
Bach FA, Muñoz Sandoval D, Mazurczyk M, Themistocleous Y, et al · · 2023 · cited 11× · PMID 37616070 · DOI 10.1172/jci152463
Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infection.
Muñoz Sandoval D, Bach FA, Ivens A, Harding AC, et al · · 2025 · cited 4× · PMID 40214640 · DOI 10.1084/jem.20241667
Diagnosis of Plasmodium falciparum malaria at very low parasitaemias using a commercially available LAMP assay and RDT.
Payne RO, Edwards NJ, Themistocleous Y, Silk SE, et al · · 2025 · cited 2× · PMID 40391391 · DOI 10.1093/trstmh/traf050
Cytotoxic T cells are silenced to induce disease tolerance in human malaria
Sandoval DM, Bach FA, Ivens A, Harding AC, et al · · 2021 · cited 2× · DOI 10.1101/2021.08.19.21262298
Repeat controlled human malaria infection of healthy UK adults with blood-stage<i>Plasmodium falciparum</i>: safety and parasite growth dynamics
Salkeld J, Themistocleous Y, Barrett JR, Mitton CH, et al · · 2022 · DOI 10.1101/2022.06.27.22276860

Verify or expand the search:

Other recruiting trials for Malaria

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03906474 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 8 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03906474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing